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GUEST EDITORIAL
Conformal therapy
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What is it? Why do it?
The term 'conformal therapy' can really be applied to any
radiotherapy technique which attempts to improve the dose
distribution in tumour and normal tissue, such that the
therapeutic gain is enhanced. In other words, it is any pro-
cess by which the high dose volume is made to conform more
closely to the ideal target volume. There is nothing new
about this approach which actually underpins all traditional
radiotherapy planning techniques. What is new is the
burgeoning technology which has revolutionised the pos-
sibilities in terms of the extent to which those aims can be
pursued and the precision with which they can be carried
out.
In conventional external beam radiotherapy planning, the
limits of the target volume are defined in two dimensions on
any one particular simulator radiograph view. Bony land-
marks provide the main anatomical reference points for
determining the position of normal tissue structures and
tumour extent. The number, shape, size and position of the
radiotherapy beams are selected optimally to deliver the pre-
scribed dose to the target volume, aiming to keep the varia-
tion in dose to within 10%. However, the assessment of the
dose distribution is usually based on a single transaxial plan,
conventionally in the middle of the volume, which obviously
fails to demonstrate dose inhomogeneities throughout the
entire treatment volume. This applies both to the target
volume where cold spots are a particular concern with regard
to tumour control and to normal tissue structures where hot
spots might indicate future morbidity.
The availability ofcomputerised tomography (CT) imaging
really established the possibility of three-dimensional plan-
ning, allowing an appreciation of the anatomical relations
throughout the treatment length. However, this information
could not be fully utilised until it was possible to link the CT
data directly to a radiotherapy planning system. The applica-
tion of computer technology has made this a reality and has
been the major contributing factor in realising the long held
aspirations behind conformal therapy. Although most
development effort has focused on external photon beam
therapy, the systems devised are also being applied to elec-
tron beam therapy, brachytherapy and combinations of
these.
But this is just the starting point. The field of computer-
aided radiotherapy systems encompasses activity in many
different areas including control of treatment machine
parameters, computer graphics, treatment verification
systems, three-dimensional dose calculations and normal tis-
sue and tumour dose response models. The aim of modern
radiotherapy is to integrate these components to provide
'better' treatments in terms of effectiveness, safety and
efficiency.
The radiation dose that can be delivered to tumours is deter-
mined by the radiation tolerance of the adjacent normal
tissues. Only for very radiosensitive tumours, such as Hodg-
kin's lymphoma and seminoma, is the effective dose range
such that normal tissues rarely influence the dose prescribed.
However, for the majority of tumours, higher radiation doses
cannot safely be delivered unless the normal tissues can be
protected or excluded in some way.
The rationale behind attempting to escalate tumour dose
lies in the assumption that the dose-response curve for
human tumours is steep. For obvious ethical reasons, reliable
clinical dose-response data are scanty. However, this is a
mass of less exacting retrospective clinical information which
suggests that for many tumours an increased probability of
tumour control would be expected if higher doses were em-
ployed (Williams et al., 1984).
As failure of local control remains an important cause of
death at a number of primary cancer sites, it is reasonable to
assume that survival rates would increase if better local
control could be achieved. For three types of pelvic tumour,
bladder, uterine cervix and corpus, data have been reviewed
which support this supposition (Suit, 1982). At these tumour
sites, salvage surgery for radiotherapy failures results in
18-34% long-term survivors. These clinical data represent
the experience of several large institutions over many years
and patients eligible for such salvage surgery cannot be
regarded as representative of all patients failing radiotherapy.
It is probable that patients suitable for an operation repre-
sent a highly favourable group, and these figures are likely to
underestimate the true potential gain to be derived from
achieving local control in every patient. Nevertheless, based
on these results, it is possible to make estimates of the
maximum survival gain to be expected from fully effective
loco-regional treatment. For example, in the United King-
dom there are just over 39,000 new registrations for pelvic
neoplasms each year and this is accompanied by the registra-
tion of over 23,000 deaths from cancer at these sites. As a
rough estimate, if a 100% local control rate could be
guaranteed by radiotherapy, then approximately half the
patients currently dying of their disease, that is approx-
imately 12,000, might be saved per year.
Fulfilling this chain of events, that is, delivery of higher
tumour dose, increasing the probability of local control and
improving survival rates, is the ultimate aim of conformal
therapy. Coincidentally, there may well be gains with regard
to reduced toxicity, both in terms of acute side-effects and
long-term morbidity. Besides the consequent improvement in
quality of life, this may have important implications for
treatment schedules combining chemotherapy with radiation
where overlapping toxicity may currently limit the applica-
tion of one, or both of these modalities.
How is it done?
The rapid evolution of computer technology has had a
radical impact on the way in which CT and, more recently, Received 23 May 1990.
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magnetic resonance imaging (MRI) data can be assimilated
for radiotherapy planning. The ability to reconstruct transax-
ial CT data and display the information in any chosen plane
has made three-dimensional planning possible. Reconstruc-
tions of the target volume and normal tissues of interest can
now be computed and viewed from any angle and, most
importantly, the trajectory of any beam can be visualised
through the body. This facility, known as beam's eye view
(BEV), permits precise localisation of the target volume and
normal tissue within the beam's path.
The challenge of the planning process is, thus, to arrange
the high dose volume to conform as closely as possible, in
terms of shape and size, with the ideal target volume. In
addition, the dose variation within the high-dose volume,
resulting from factors such as body contouring and tissue
inhomogeneity, must be examined throughout the target
volume and attempts made to produce as uniform a dose
distribution as possible.
The first of these requirements generally involves some
form of field shaping. Standard collimator design limits
radiation beams to square or rectangular shapes but these
can be modified, quite simply, by inserting custom-designed
blocks within the path of the beam. Customised blocks of
this sort have been in use in some centres for many years, but
only relatively recently has the construction of these blocks
been based on three-dimensional CT information. Another
means of shaping radiotherapy fields is to use what is known
as a multi-leafed collimator. With this facility, rather than
having a straight fixed edge, the collimator is made up of a
number of leaves each capable of independent movement
under computer control. Thus, depending on the number of
leaves per collimator, the beam edge can be shaped as
required. This facility cuts the time (and money) involved in
the manufacturing of customised blocks and should reduce
the setting-up time of the treatment machine.
Adjustment of treatment machine parameters whilst the
radiation beam is turned on is termed 'dynamic therapy', and
this feature can also be used to facilitate beam shaping. For
example, adjustment of the position of the collimators in the
transverse plane, while the beam is swept along the length of
the treatment volume, will contour the field. Another form of
dynamic therapy which permits beam shaping is the scanning
beam, in which pencil beams of radiation are scanned back-
wards and forwards across the target volume, with the extent
of the scan defining the shape of the beam (Brahme, 1987).
The second requirement of conformal therapy, improved
dose distribution within the target volume, is also facilitated
by dynamic therapy. A simple example of this is the use of
the computer-controlled independent collimator action to
produce the equivalent of a wedged field. This is done by
moving the appropriate collimator across the field with the
result that the beam is attenuated in the same way as is
achieved by introducing a manual wedge.
Selection of the optimal conformal plan for any given
patient requires the clinician to be able to assimilate an
enormous quantity of data. The ability to reconstruct CT
data, with superimposition of the isodoses, in any chosen
plan facilitates both the ordering and interpretation of this
information. However, the development of analytical tools
such as dose-volume histograms has made it easier to
evaluate, and directly compare, treatment plans.
Dose-volume histograms are a means of graphically sum-
marising dose distribution information throughout a normal
tissue structure or target volume by plotting percentage
volumes of tissue against radiation dose levels. By comparing
dose-volume histograms for competing plans, an immediate
appreciation of the benefits and shortcomings can be ascer-
tained.
Is it worth it?
The attractions of conformal therapy for clinicians and
physicists are obvious, as exemplified by the explosion of
interest and activity in the field. However, there has been
very little in the way of well-designed evaluation of the
components, or the overall achievement, of the technique.
This is essential - conformal therapy is not an assured winner
in clinical terms, but is a definite absorber of resources from
the point of view of capital expenditure and manpower.
The core danger is that without adequate monitoring of
the precision and accuracy of the components of the techni-
que, in certain situations, local control may in fact be worse.
One concern is that over-reliance on imaging techniques to
define tumour extent, together with a commendable enthusi-
asm to spare normal tissues, may result in inadequate treat-
ment margins. This potential risk may be compounded by
inaccuracy in the daily treatment set-up such that an area at
the edge of the treatment volume may be consistently under-
dosed. No matter how elegant and sophisticated the treat-
ment plan, success is unlikely if it is applied to a tense,
anxious or pain-ridden patient who cannot maintain the
same position from day to day, or indeed for the duration of
each daily treatment. Currently, a great deal of effort, world-
wide, is being put into developing systems which image the
patient during treatment so that variation in patient position-
ing and/or machine alignment can be monitored and cor-
rected. However, there must be assurance that all the
elements of the planning and treatment process have an
equivalent degree of accuracy and that such errors as are
unavoidable are taken into account when designing the plan.
This means that each of the technical components of the
process must be individually validated and then the sequence
tested as a whole.
Technical precision having been ensured, the next step is to
address clinical and biological questions on the basis of a
comparison with the best available standard radiation treat-
ment techniques. This requires well designed prospective
studies which will clearly identify the differences, and the size
and frequency of those differences, between the two techni-
ques (Tait et al., 1988). If the philosophy is that conformal
therapy will allow higher doses to be delivered to tumour
without a parallel increased risk of morbidity, then the
hypothesis must be tested in two stages. Firstly, can the
available conformal techniques bring about sufficient reduc-
tion in normal tissue irradiation to alter the incidence and/
or, severity or toxicity? Although a volume effect for normal
tissue tolerance is generally assumed, there is a dearth of
precise clinical information to support this or to identify
which sites, and what volume, within a tissue or organ, is
most critical in terms of functional outcome. Secondly, if the
answer to the normal tissue question is in the affirmative,
then the question of tumour dose escalation can be ad-
dressed. These questions need to be applied to the common
radiotherapy treatment sites where local control remains a
determinant of survival. The obvious choices are the pelvis
and head and neck region, and the necessary structure is the
randomised trial. The relevant tools for comparison are
dose-volume analyses for normal tissues and target volumes,
and time-cost evaluation. But the key question is how do
these parameters correlate with clinical outcome from the
point of view of toxicity and tumour control? The ongoing
Royal Marsden Hospital trial of conformal radiotherapy for
pelvic tumours has been designed to answer precisely these
questions.
What the speciality really wants to know about conformal
therapy is where is it likely to be ofbenefit, in terms of which
patients with what tumours, and what is the likely size of
that benefit? In other words, in what situations is it worth the
investment and where is it an unnecessary extravagance? To
what extent should individual departments strive to embrace
these developments? The new technology is obviously
exciting in terms of the potential for improvement in
therapeutic ratio, but this potential must be translated into
proven benefits in order that the specialty can demonstrate a
clear advance and plan for future developments.704 D. TAIT
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